soul trial oral semaglutide cardiovascular outcomes 2024 nejm results and in Patients with Type 2 Diabetes SELECT Trial

De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zang E, Reimann F, Rosengren AH, Shibasaki T, Gribble F, Renstrm E, Seino S, Eliasson L, Rorsman P: GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis

If youre unsure how much you should be drinking, what fluids are best, or how to stay hydrated when your appetite is low, you're not alone

doi: 10.1016/j.gie.2024.12.019

DHEA in women plays a critical role in producing adequate amounts of the right hormones to maintain homeostasis and harmony within the body

29 Another valuable study would be a prospective randomized clinical trial with well-designed primary ocular outcomes comparing the GLP-1/GIP agonists to another diabetes drug class, such as the SLGT inhibitors, which has the same target hemoglobin A1c reduction in both treatment arms